GlaxoSmithKline
Do more, feel better, live longer
Investors
Corporate press releases
[an error occurred while processing this directive] [an error occurred while processing this directive]06 November 2009
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine
Latest documents
29 September 2009
Raymond James Vaccines Conference
Dr Thomas Breuer, Senior Vice President Global Clinical R&D Vaccines & Chief Medical Officer, GSK Biologicals, gave a presentation to a group of around 40 investors on 28 September in Paris. Thomas provided an overview of GSK's vaccines business and late-stage pipeline.
Q3 results 2009
Product pipeline
Share price
LSE
1254p
+13.00
21 Nov 2009 12:50pm GMT
NYSE
41.53
0.00
21 Nov 2009 closed
GSK's strategic priorities
Product pipeline
Building the best product pipeline in the industry
We aim to create the best product pipeline in the industry for the benefit of patients, consumers and society.
Our R&D organisation measures productivity by the number and innovation of the products it creates, and also by the commercial value of the products.
Find out more about our pipeline 